Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat
- PMID: 6819097
- DOI: 10.1007/BF00257229
Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat
Abstract
The effect of pretreatment with cyclophosphamide 180 mg/kg upon the short-term disposition of adriamycin in anesthetized rat 4 days later was studied. There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats. Biliary excretion of adriamycin over 2.5 h was increased significantly by 114% in cyclophosphamide-pretreated rats and there was a small but nonsignificant increase in biliary adriamycinol excretion and a decrease in excretion of adriamycin aglycones. Cyclophosphamide pretreatment was associated with an 83% increase in bile flow. Cyclophosphamide pretreatment had no significant effect upon the utilization of adriamycin or upon the formation of adriamycin metabolites by rat isolated hepatocytes. The results suggest that NADPH-cytochrome P-450 reductase, which is decreased 40% by cyclophosphamide pretreatment, is not rate-limiting in elimination of adriamycin. Biliary excretion of adriamycin is increased when plasma adriamycin clearance is decreased, suggesting that cyclophosphamide pretreatment affects a pathway besides biliary excretion that is responsible for the short-term removal of adriamycin from plasma.
Similar articles
-
Bilary disposition of adriamycin.Clin Pharmacol Ther. 1977 Aug;22(2):234-41. doi: 10.1002/cpt1977222234. Clin Pharmacol Ther. 1977. PMID: 884924
-
Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.Cancer Chemother Pharmacol. 1996;37(5):472-8. doi: 10.1007/s002800050414. Cancer Chemother Pharmacol. 1996. PMID: 8599871
-
Interactions between cyclophosphamide and adriamycin metabolism in rats.J Pharmacol Exp Ther. 1984 Apr;229(1):51-7. J Pharmacol Exp Ther. 1984. PMID: 6423814
-
Bile secretory function: a determinant of adriamycin disposition.Arch Int Pharmacodyn Ther. 1980 Jun;245(2):180-97. Arch Int Pharmacodyn Ther. 1980. PMID: 7406604
-
Metabolic activation of adriamycin by NADPH-cytochrome P-450 reductase, rat liver and heart microsomes and covalent protein binding of metabolites.Adv Exp Med Biol. 1981;136 Pt A:471-85. doi: 10.1007/978-1-4757-0674-1_36. Adv Exp Med Biol. 1981. PMID: 6807062 No abstract available.
Cited by
-
Pharmacokinetic drug interactions of commonly used anticancer drugs.Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004. Clin Pharmacokinet. 1986. PMID: 2426030 Review.
-
Variability in the pharmacokinetics of epirubicin: a population analysis.Cancer Chemother Pharmacol. 1992;29(5):391-5. doi: 10.1007/BF00686009. Cancer Chemother Pharmacol. 1992. PMID: 1551178
-
Hepatic metabolism of doxorubicin in mice and rats.Eur J Drug Metab Pharmacokinet. 1986 Apr-Jun;11(2):101-5. doi: 10.1007/BF03189834. Eur J Drug Metab Pharmacokinet. 1986. PMID: 3770010
-
Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.Cancer Chemother Pharmacol. 1987;19(3):240-5. doi: 10.1007/BF00252979. Cancer Chemother Pharmacol. 1987. PMID: 3581417